A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients
The development of angiotensin-converting enzyme inhibitors (ACE inhibitors) has been one of the most remarkable stories in the treatment of cardiovascular diseases. Angiotensin converting enzyme inhibitors have several acute and sustained hemodynamic effects that are beneficial in the presence of left ventricular (LV) dysfunction. They increase cardiac output and stroke volume and reduce systemic vascular resistance as well as pulmonary capillary wedge pressure. The hemodynamic benefits are associated with improvement in the signs and symptoms of congestive heart failure (CHF) as well as decreased mortality, regardless of the severity of CHF. In patients with asymptomatic LV dysfunction, therapy with ACE inhibitors prevented the development of CHF and reduced hospitalization and cardiovascular death. They also increase survival when administered early after an acute myocardial infarction (MI). Most recently, ACE inhibition was associated with improved clinical outcomes in a broad spectrum of high-risk patients with preserved LV function. The mechanism of ACE inhibitors benefits is multifactorial and includes prevention of progressive LV remodeling, prevention of sudden death and arrhythmogenicity and structural stability of th...Continue Reading
Renin, aldosterone and cardiac decompensation: studies with an oral converting enzyme inhibitor in heart failure
Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction
Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. The Benazepril Heart Failure Study Group
Effects of enalapril on long-term mortality in severe congestive heart failure. CONSENSUS Trial Group
Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension.
Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system
Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction
Acute effects of delayed reperfusion on myocardial infarct shape and left ventricular volume: a potential mechanism of additional benefits from thrombolytic therapy
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril
Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy
Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor
A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group
Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function
ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group
Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1)
GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators
Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure
The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators
Discrepancy between plasma and lung angiotensin-converting enzyme activity in experimental congestive heart failure. A novel aspect of endothelium dysfunction
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators
Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use
Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the "PRACTICAL" study)
Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study
Can the premises of the altered homeostatic theory permit improvement in the prevention of ischemic heart disease?
Can the premises of the spasm of resistance vessel concept permit improvement in the treatment and prevention of ischemic heart disease?
Innovation in basic science: stem cells and their role in the treatment of paediatric cardiac failure--opportunities and challenges
Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough
Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis
Accumulation of fibronectin in the heart after myocardial infarction: a putative stimulator of adhesion and proliferation of adipose-derived stem cells.
Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough
Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data
The dilemma, causes and approaches to avoid recurrent hospital readmissions for patients with chronic heart failure.
Low ejection fraction documented during cardiac catheterization is significantly associated with long-term, all-cause mortality
An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors
Effects of combined inhibition of the Na+-H+ exchanger and angiotensin-converting enzyme in rats with congestive heart failure after myocardial infarction
Assay of free captopril in human plasma as monobromobimane derivative, using RPLC/(+)ESI/MS/MS: validation aspects and bioequivalence evaluation
Is "hyper response" to cardiac resynchronization therapy in patients with nonischemic cardiomyopathy a recovery, a remission, or a control?
Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial
The effects of angiotensin II signaling pathway in the systolic response to acute stretch in the normal and ischemic myocardium
One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry)
Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies
Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: A UK population-based study
Retinal angiotensin II and angiotensin-(1-7) response to hyperglycemia and an intervention with captopril
Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association
Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy
Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction
Genetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: A systematic review and evaluation of methodological approaches
A systematic review of pharmacologic therapies for the cardiomyopathy of Duchenne muscular dystrophy.
The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease
Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction
Arrhythmogenic Right Ventricular Dysplasia
Arrhythmogenic right ventricular dysplasia is a congenital cardiomyopathy that is characterized by infiltration of adipose and fibrous tissue into the right ventricle wall and loss of myocardial cells. Primary injuries usually are at the free wall of the right ventricular and right atria resulting in ventricular and supraventricular arrhythmias. Discover the latest research on arrhythmogenic right ventricular dysplasia here.
Discover the latest cardiology research in this collection of the top cardiology journals.
Cardiovascular Disease Pathophysiology
Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.